The Board

The Board


The board of Swedish Society of Toxicology is elected once a year at the annual meeting. It is the task of nominating committee to nominate the candidates to different position on the board. The current board were elected during the annual meeting on 9 april 2021.


Oskar Karlsson

Chairman

Oskar Karlsson has been a member of the board of SFT since 2019


Oskar Karlsson is a Pharmacist and Associate Professor at SciLifeLab, Department of Environmental Science and Analytical Chemistry, Stockholm University. He earned a PhD in Toxicology at Uppsala University in 2011, and has previously worked at Karolinska Institute and Harvard University. His research groupcombines experimental model systems and molecular epidemiology to study effects of environmental contaminants.

Klara Midander

Vice Chairman

Klara Midander has been a member of the board of SFT since 2020  


Klara is active at the Institute of Environmental Medicine, Karolinska Institutet, and shares her time as a researcher in areas related to exposure and effects of toxic and allergenic metals, with applied work as coordinator at the National Platform for Nanosafety, SweNanoSafe. "My engineering background in chemistry and physics (MSc, Chalmers) as well as surface- and materials science (PhD, KTH) is very useful in the interdisciplinary environment at IMM and I also hope to contribute with my experience in the board of STF.

Lizette Granberg

Secretary

Lizette Granberg has been a member of the board of SFT since 2020 


Lizette is working at TKT since 2018 as a consultant in toxicology, providing project support in preclinical safety assessment and environmental risk assessment of pharmaceuticals. She also works with hazard classification of chemicals and risk assessment for occupational exposure. Lizette earned a PhD in Environmental toxicology at Uppsala University in 2001, and has previously worked at AstraZeneca in Södertälje.

Susann Busch

Treasurer

Susann Busch has been a co-opt board member since November 2019 and she became treasurer in 2020.


Susann Busch did her PhD at Friedrich-Schiller University Jena, Germany in 2008, then worked as a post-doc at Manchester University, UK before joining the Sahlgrenska Academy, Gothenburg. Since 2017, Susann work as a Senior Scientist in Clinical Pharmacology and Safety Sciences (CPSS) at AstraZeneca in Gothenburg.

Jenny Aasa

Board Member

Jenny Aasa has been a member of the board of SFT since 2020  


Jenny Aasa is originally a pharmacist and an analytical chemist. Between the years 2002-2012 she worked at AstraZeneca in Södertälje with research regarding metabolism and enzymology. She has a PhD degree in environmental chemistry from Stockholm University, 2018. The thesis was about cancer risk assessment of glycidol, a genotoxic contaminant in edible cooking oils. Since 2019 she works as a toxicologist at the Swedish Food Agency.

Linnea Nilsson

Board Member

Linnea Nilsson has been a member of the board of SFT since 2022  


Linnea Nilsson has worked at AstraZeneca as an Occupational Toxicologist since 2016, mostly with risk assessments of in-house substances from an occupational perspective, but also with cross-contamination and other parts of quality toxicology as well as other regulatory questions. Linnea has earlier worked at IKEM - Innovation and Chemical Industries, with advocacy and public relations and before that at a smaller pharmaceutical company with occupational toxicology, risk assessment and regulatory questions. Linnea gratuated from the Toxicology program at the Karolinska Institutet.

Joachim Sturve

Board Member

Joachim Sturve has been a member of the board of SFT since 2022  


.

.

.

.

.

.

.

Sara Moses

Board Member

Sara Moses has been a member of the board of SFT since 2021


Sara has a background as a project toxicologist from the pharmaceutical industry and is today a team leader of two teams at Swedish Match: Nonclinical Science and Regulatory and Product Safety. Her toxicological focus is within product safety, from design and performance of different in vitro studies, acceptable limit values to regulatory issues and applications to authorities.